Compare GTN & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTN | PACB |
|---|---|---|
| Founded | 1897 | 2000 |
| Country | United States | United States |
| Employees | 9582 | N/A |
| Industry | Broadcasting | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 446.1M | 419.8M |
| IPO Year | N/A | 2010 |
| Metric | GTN | PACB |
|---|---|---|
| Price | $5.71 | $1.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $8.50 | $1.67 |
| AVG Volume (30 Days) | 1.1M | ★ 5.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | $13.89 | $11.32 |
| Revenue Next Year | N/A | $12.13 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $3.13 | $0.85 |
| 52 Week High | $6.31 | $2.73 |
| Indicator | GTN | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 70.82 | 60.66 |
| Support Level | $5.50 | $1.52 |
| Resistance Level | $6.04 | $1.64 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 95.12 | 93.80 |
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios. The company's segments include Broadcasting and Production Companies. The majority of revenue is derived from broadcast and digital advertising and from retransmission consent fees.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.